MyFinsight
Home
Blog
About
Net change in cash,
cash equivalents and...
-$19,715K
(4.42%↑ Y/Y)
Share-based compensation
$4,822K
(-9.10%↓ Y/Y)
Accrued expenses
$3,585K
(-23.80%↓ Y/Y)
Accounts payable
$2,000K
(478.03%↑ Y/Y)
Rou asset
amortization
$355K
(-27.70%↓ Y/Y)
Depreciation and
amortization
$21K
(-91.25%↓ Y/Y)
Proceeds from sale or
maturities of marketable...
$35,814K
(-43.38%↓ Y/Y)
Net cash used in
operating activities
-$14,738K
(41.14%↑ Y/Y)
Net cash provided by
investing activities
-$4,977K
(-195.20%↓ Y/Y)
Canceled cashflow
$10,783K
Canceled cashflow
$35,814K
Net loss
-$25,154K
(31.11%↑ Y/Y)
Purchases of marketable
securities
$40,615K
(-29.98%↓ Y/Y)
Amortization of premium and
discount on marketable...
-$198K
(-94.12%↓ Y/Y)
Operating lease liability
-$158K
(46.26%↑ Y/Y)
Prepaid expenses and
other current assets
$11K
(101.40%↑ Y/Y)
Purchase of property and
equipment
$176K
(877.78%↑ Y/Y)
Back
Back
Cash Flow
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)
source: myfinsight.com